Liver Cancer Trial, Recruiting NCT04491929 Sponsor: Aarhus University Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT04491929
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with colorectal cancer that has spread (metastasized) to the liver, and the liver is the main area affected.
  • Your liver metastasis has been confirmed either through a tissue/cell sample (biopsy) or through scans and clinical assessment.
  • Your liver tumors cannot be removed by surgery, or treated with heat ablation (RFA) or a focused radiation technique (SBRT).
  • You have stopped all chemotherapy at least 14 days before the planned treatment in this trial.
  • You have stopped any medications that block blood vessel growth (such as bevacizumab) at least 6 weeks before the planned treatment.
  • Your cancer has gotten worse, or you had serious side effects from, all standard chemotherapy treatments available to you.
  • You are generally well enough to carry out daily activities with little or no limitation (confirm with trial site).
  • You are 18 years old or older.
  • You are able to read and understand written information.
  • You agree to provide samples for research purposes.

Who may not be able to join:

  • A pre-treatment scan using a special tracer (a radioactive substance used to check blood flow) shows it is reaching the digestive tract (stomach or bowel) in a way that cannot be corrected.
  • Evidence that the tracer is reaching the stomach or the upper part of the small intestine, even after attempts to prevent this.
  • You have previously had radiation therapy to your lungs or upper abdomen in a way that overlaps with the liver (confirm with trial site).
  • The pre-treatment scan shows too much of the tracer going to your lungs (over 20%, or a radiation dose above 30 Gray to the lungs).
  • You are pregnant.
  • You have active lung disease that would make this treatment unsafe (confirm with trial site).
  • You have an active infection that is not under control.
  • Recent blood tests (within 30 days) show your liver is not functioning well enough — specifically, certain liver enzymes or bilirubin levels are too high.
  • You currently have, or have previously had, fluid buildup in the abdomen (ascites), confirmed by scan or physical examination.
  • Your tumors take up more than 50% of your total liver volume.
  • You are unable or unwilling to provide samples for research purposes.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Louise B Callesen, Experimental Clinical Oncology

Phone: +4578462535

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Aarhus University Hospital
Registry
ClinicalTrials.gov
Start date
1 November 2020
Est. completion
28 February 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Feasibility and translational analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov